CN104086502B - 卤代四氮唑苯乙酮化合物、其制备方法和用途 - Google Patents
卤代四氮唑苯乙酮化合物、其制备方法和用途 Download PDFInfo
- Publication number
- CN104086502B CN104086502B CN201410352039.XA CN201410352039A CN104086502B CN 104086502 B CN104086502 B CN 104086502B CN 201410352039 A CN201410352039 A CN 201410352039A CN 104086502 B CN104086502 B CN 104086502B
- Authority
- CN
- China
- Prior art keywords
- compound
- preparation
- tetrazole
- halo
- par
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title abstract description 6
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Natural products CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 title description 2
- -1 Halo tetrazole acetophenone compound Chemical class 0.000 title description 2
- 239000003814 drug Substances 0.000 claims abstract description 11
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940098892 Protease-activated receptor-1 antagonist Drugs 0.000 abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 102000032626 PAR-1 Receptor Human genes 0.000 description 8
- 108010070519 PAR-1 Receptor Proteins 0.000 description 8
- 239000003146 anticoagulant agent Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 206010003178 Arterial thrombosis Diseases 0.000 description 7
- 210000001772 blood platelet Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000003790 Thrombin receptors Human genes 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- FHZSIZRTNHGLSX-FLMSMKGQSA-N (2s)-1-[(2s)-4-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-oxobutanoyl]pyrrolidine-2-carboxyl Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 FHZSIZRTNHGLSX-FLMSMKGQSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- 230000000702 anti-platelet effect Effects 0.000 description 3
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 108010093640 thrombin receptor peptide SFLLRNP Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108090000166 Thrombin receptors Proteins 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 0 CC(C)(C)c(cc(cc1N2CCOCC2)C(CN2I=NC(c(cc3)c(*)cc3O*)=*CC2)=O)c1OC Chemical compound CC(C)(C)c(cc(cc1N2CCOCC2)C(CN2I=NC(c(cc3)c(*)cc3O*)=*CC2)=O)c1OC 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229960000711 alprostadil Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 229940127217 antithrombotic drug Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 238000007395 thrombosis prophylaxis Methods 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940019333 vitamin k antagonists Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及与血栓性疾病相关的药物领域。具体而言，本发明涉及一类新的卤代含四氮唑苯乙酮结构的PAR-1拮抗剂、其制备方法、及含有它们的药物组合物以及它们在制备治疗血栓性疾病药物中的应用。
Description
技术领域
本发明涉及与血栓疾病相关的药物领域。具体而言，本发明涉及对血栓性疾病有治疗作用的一类新的卤代含四氮唑苯乙酮结构的PAR-1拮抗剂及其制备方法，以及含有它们的药物组合物。
背景技术
蛋白酶激活受体1 (Protease Activated Acceptor-1，PAR-1)是最近发现的抗血小板类抗血栓药物的新靶点。蛋白酶激活受体1又叫凝血酶受体，凝血酶被凝血连锁激活后通过PAR-1受体作用于血小板从而激活血小板，引起血小板聚集从而引起血栓和凝血。PAR-1引起的血栓中富含血小板成分，是动脉血栓的主要成因。PAR-1拮抗剂能阻断凝血酶激活血小板，从而阻断动脉血栓形成，可以用于治疗急性冠状动脉疾病(Acute Coronary Syndrome)。已经有几个PAR-1抑制剂处于临床研究(Chackalamannil S., Thrombin Receptor (Protease Activated Receptor-1) Antagonists as Potent Antithrombotic Agents with Strong Antiplatelet Effects, J. Med. Chem., 2006, 49(18), 5389-5403)。
传统的用于防治血栓性疾病的药物分为三类。第一类是抗凝血类，分为直接凝血酶抑制剂和间接凝血酶抑制剂，该类药物通过作用于凝血连锁的不同环节来抑制血栓形成，具有抑制各种血栓形成的作用，如维生素K拮抗剂和Xa因子抑制剂等；第二类是抗血小板类，如COX-1抑制剂和ADP受体拮抗剂等，该类药物主要用于防治动脉血栓；第三类是纤维蛋白溶解剂，主要用于溶解血液中形成的纤维蛋白。
抗血小板药物多是传统的动脉血栓防治药物，如氯吡格雷和阿司匹林等。这些药物的缺点是出血风险比较大。而作为新发现的抗血小板类抗血栓药物的PAR-1拮抗剂，则具有较小的出血风险，因此这类化合物可以作为治疗动脉血栓的很有前景的药物。
本发明公开了一类卤素取代的含四氮唑苯乙酮结构的PAR-1拮抗剂，可以用于制备抗动脉血栓疾病的药物。
发明内容
本发明的一个目的是提供一种具有良好抗血栓形成活性的具有通式I的化合物及其药学上可以接受的盐。
本发明的另一个目的是提供制备具有通式I的化合物及其药学上可以接受的盐的方法。
本发明的再一个目的是提供含有通式I的化合物及其药学上可以接受的盐作为有效成分，以及一种或多种药学上可接受的载体、赋形剂或稀释剂的药用组合物，及其在治疗动脉血栓方面的应用。
现结合本发明的目的对本发明内容进行具体描述。
本发明具有通式I的化合物具有下述结构式：
( I )
其中，
R1选自卤素取代基；
R2选自C1-C5的烷基、环烷基。
优选以下具有通式I的化合物，
其中，
R1选自F、Cl、Br、I；
R2选自C1-C3的烷基。
进一步，优选以下具有通式I的化合物，
更进一步，优选以下具有通式I的化合物，
本发明所述通式I化合物通过以下步骤合成：
。
化合物II和化合物III在酸或者碱的催化下反应，得到化合物(I)。
本发明所述式I化合物的药学上可接受的盐，包括但是不限于与各种无机酸如盐酸、硫酸、硝酸、磷酸、氢溴酸等形成的盐，也包括与各种有机酸如乙酸、琥珀酸、马来酸、苹果酸以及各种氨基酸等形成的盐。
本发明所述通式I化合物具有PAR-1的拮抗作用，可作为有效成分用于制备抗血栓方面的治疗药物。本发明所述通式I化合物的活性是通过体外模型验证的。
本发明的通式I化合物在相当宽的剂量范围内是有效的。例如每天服用的剂量约在1 mg-500 mg/人范围内，分为一次或数次给药。实际服用本发明通式I化合物的剂量可由医生根据有关的情况来决定。这些情况包括：被治疗者的身体状态、给药途径、年龄、体重、对药物的个体反应，症状的严重程度等。
具体实施方式
下面结合实施例对本发明作进一步的说明。需要说明的是，下述实施例仅是用于说明，而并非用于限制本发明。本领域技术人员根据本发明的教导所做出的各种变化均应在本申请权利要求所要求的保护范围之内。
实施例1
。
反应原料：自制，常规方法。
2.10 g (10 mmol)化合物II-1、3.70 g (10 mmol)化合物III-1和4.15 g (30 mmol)固体碳酸钾在20 mL乙腈中搅拌过夜，而后升温回流3小时。
反应混合物稍冷后倾倒到200 mL冰水中，搅拌，用浓盐酸调节pH = 4，50 mL × 3的二氯甲烷萃取，合并有机相，食盐水洗涤，无水硫酸钠干燥，在旋转蒸发仪上蒸去溶剂，得到的残余物经过柱层析纯化，得到纯品I-1，白色固体，MS, m/z = 523([M+Na]+)。
实施例2-6
按照实施例1的方法，合成了具有通式I的下列化合物。
实施例7 体外血小板聚集抑制试验
在96孔板中，在TRAP(凝血酶受体活化肽)诱导的血小板聚集中进行物质的药理学试验。注射器中预先加入3.13%的柠檬酸钠溶液，然后抽入20 mL健康志愿者的血液，在1500 g下离心20分钟，将富含血小板的血浆(PRP)分离出来并以1 μL PGE1溶液(500 μg/mL的乙醇溶液)/mL PRP的量进行处理。在室温下孵育5分钟后，将其在1200 g下离心20分钟以除去白细胞。将不含白细胞的PRP以5 mL/份分批转移到15 mL的PP管中，并在3600 g下离心使血小板沉淀。而后，滗出上层血浆，将得自5 mL PRP的血小板沉淀重新混悬于1 mL Tyrode (120 mM NaCl，2.6 mM KCl，12 mM NaHCO3，0.39 mM NaH2PO4，10 mM HEPES，0.35% BSA，5.5 mM葡萄糖，pH = 7.4)中，并用Tyrode调节至3×105/μL的血小板计数。将13 mL这种细胞混悬液用866 μL的10 mM CaCl2溶液处理，以每孔120 μL的量将其吸至96孔板中，在96孔板的孔中已经提前加入了15 μL待测试物质。在室温下黑暗中孵育30分钟，加入15 μL TRAP溶液(70-100 μM)作为激动剂，在SpectraMax中37°C 下振荡20分钟，在650 nm下纪录动力学，计算阴性对照(tyrode/DMSO)和阳性对照(15 μL激动剂/DMSO)的曲线下面积，并将差异定为100%。将待测试化合物以系列稀释物的形式吸移，一式两份地进行测定，同样测定各物质浓度的AUC，计算与对照相比的AUC抑制%。通过该抑制%按照4参数方程借助非线性回归分析计算IC50值。下表给出了结果。
从上表可以看出，本发明的化合物在血小板凝聚试验中均表现出明显的抑制作用。
Claims (3)
1.下列化合物及其药学上可以接受的盐，
2.权利要求1所述化合物及其药学上可以接受的盐，选自，
3.权利要求1或2任一所述化合物及其药学上可以接受的盐在制备治疗血栓性药物方面的用途。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410352039.XA CN104086502B (zh) | 2014-07-23 | 2014-07-23 | 卤代四氮唑苯乙酮化合物、其制备方法和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410352039.XA CN104086502B (zh) | 2014-07-23 | 2014-07-23 | 卤代四氮唑苯乙酮化合物、其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104086502A CN104086502A (zh) | 2014-10-08 |
| CN104086502B true CN104086502B (zh) | 2015-10-14 |
Family
ID=51634292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410352039.XA Active CN104086502B (zh) | 2014-07-23 | 2014-07-23 | 卤代四氮唑苯乙酮化合物、其制备方法和用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104086502B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104529928A (zh) * | 2015-01-13 | 2015-04-22 | 佛山市赛维斯医药科技有限公司 | 一类恶二唑亚砜化合物、其制备方法和用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL130286A0 (en) * | 1996-12-23 | 2000-06-01 | Du Pont Pharm Co | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| WO1998057937A2 (en) * | 1997-06-19 | 1998-12-23 | The Du Pont Merck Pharmaceutical Company | Inhibitors of factor xa with a neutral p1 specificity group |
| IL136637A0 (en) * | 1997-12-22 | 2001-06-14 | Du Pont Pharm Co | Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors |
| DE102004003812A1 (de) * | 2004-01-25 | 2005-08-11 | Aventis Pharma Deutschland Gmbh | Arylsubstituierte Heterozyklen, Verfahren ihrer Herstellung und ihre Verwendung als Arzneimittel |
-
2014
- 2014-07-23 CN CN201410352039.XA patent/CN104086502B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104086502A (zh) | 2014-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104072436B (zh) | 对位取代的四氮唑苯乙酮化合物、其制备方法和用途 | |
| CN104072434B (zh) | 间位取代的四氮唑苯乙酮化合物、其制备方法和用途 | |
| CN104098520B (zh) | 苯基三唑希夫碱类化合物、其制备方法和用途 | |
| CN104072438B (zh) | 二烷氧代四氮唑苯乙酮化合物、其制备方法和用途 | |
| CN104072439B (zh) | 卤素取代的四氮唑苯乙酮化合物、其制备方法和用途 | |
| CN104072437B (zh) | 双取代的四氮唑苯乙酮化合物、其制备方法和用途 | |
| CN104529927A (zh) | 一类含卤代苯的恶二唑亚砜化合物、其制备方法和用途 | |
| CN104086503B (zh) | Par-1拮抗剂及其用途 | |
| CN104086502B (zh) | 卤代四氮唑苯乙酮化合物、其制备方法和用途 | |
| CN104072435B (zh) | 双烷基取代的四氮唑苯乙酮化合物和用途 | |
| CN104140398B (zh) | 甲基三唑希夫碱类结构的化合物、其制备方法和用途 | |
| CN104086494B (zh) | 末端双取代的甲基三唑希夫碱结构化合物、其制备方法和用途 | |
| CN104072432B (zh) | 含苯基取代三唑希夫碱类结构的化合物、其制备方法和用途 | |
| CN104086495B (zh) | 末端双取代的三唑希夫碱结构化合物、其制备方法和用途 | |
| CN104086497B (zh) | 三唑希夫碱类化合物、其制备方法和用途 | |
| CN104086498B (zh) | 末端取代的三唑希夫碱类结构的化合物、其制备方法和用途 | |
| CN104086493B (zh) | 末端取代的苯基三唑希夫碱结构的化合物及其用途 | |
| CN104072431B (zh) | 烷氧基取代的苯基三唑希夫碱结构的化合物及用途 | |
| CN104086500B (zh) | 一种par-1拮抗剂及其用途 | |
| CN104086496B (zh) | 一种抗血栓化合物、其制备方法和用途 | |
| CN104529930B (zh) | 一类含腈基苯的噁二唑亚砜化合物、其制备方法和用途 | |
| CN104529931B (zh) | 一类含烷氧对位取代苯的恶二唑亚砜化合物、其制备方法和用途 | |
| CN104529929B (zh) | 含烷氧取代苯的恶二唑亚砜化合物、其制备方法和用途 | |
| CN104356094B (zh) | 反式环己烷酰胺类化合物、其制备方法和在医药上的用途 | |
| CN104356059B (zh) | 含卤代吡啶基的反式环己烷酰胺类化合物及用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zuo Binhai Inventor after: Zhao Hongsheng Inventor after: Fu Changan Inventor after: Li Zhenyu Inventor before: Zhang Yuanqiang |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170731 Address after: Sanzao town Jinwan District Guangdong 519040 Zhuhai Province Anji Road No. 215 Patentee after: Zhuhai excellent Pharmaceutical Technology Co., Ltd. Address before: 528000 Guangdong, Foshan District, Pu Lan Road, the first floor of the first floor, No. 5, Chancheng Patentee before: Zhang Yuanqiang |